Orchestra BioMed Holdings (OBIO) Cash & Equivalents (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Cash & Equivalents for 7 consecutive years, with $28.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 54.61% year-over-year to $28.4 million; the TTM figure through Mar 2026 stood at $28.4 million (up 54.61% YoY), while the FY2025 annual figure was $84.6 million, up 48.97% from the prior year.
• Cash & Equivalents retreated to $28.4 million in Q1 2026 per OBIO's latest filing, from $84.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $114.6 million in Q2 2023 and bottomed at $735217.0 in Q3 2022.
• Historically, Cash & Equivalents has averaged $34.5 million across 5 years, with a median of $23.3 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents jumped 8666.88% — and 2025, when it slumped 65.24%.
• Orchestra BioMed Holdings' Cash & Equivalents stood at $19.8 million in 2022, then soared by 54.46% to $30.6 million in 2023, then jumped by 85.87% to $56.8 million in 2024, then surged by 48.97% to $84.6 million in 2025, then slumped by 66.47% to $28.4 million in 2026.
• Business Quant data shows OBIO's Cash & Equivalents at $28.4 million in Q1 2026, $84.6 million in Q4 2025, and $42.0 million in Q3 2025.